{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:24Z","timestamp":1792057344525,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-026-19100-7","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:20:35Z","timestamp":1770481235000},"page":"4510-4517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen"],"prefix":"10.1245","volume":"33","author":[{"given":"Natasha J. Stonebanks","family":"Cuillerier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Almarzooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Villareal-Corpuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sabboobeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyne","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"4","key":"19100_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrclinonc.2015.8","volume":"12","author":"M Morrow","year":"2015","unstructured":"Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015;12(4):227\u201338.","journal-title":"Nat Rev Clin Oncol"},{"key":"19100_CR2","doi-asserted-by":"publisher","first-page":"117822342110702","DOI":"10.1177\/11782234211070217","volume":"16","author":"MC Braasch","year":"2022","unstructured":"Braasch MC, Amin AL, Balanoff CR, et al. Prognostic significance of lobular carcinoma in-situ (LCIS) diagnosed alongside invasive breast cancer. Breast Cancer (Auckl). 2022;16:11782234211070216.","journal-title":"Breast Cancer (Auckl)"},{"issue":"33","key":"19100_CR3","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","volume":"33","author":"TA King","year":"2015","unstructured":"King TA, Pilewskie M, Muhsen S, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945\u201352.","journal-title":"J Clin Oncol"},{"issue":"11","key":"19100_CR4","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1001\/jamainternmed.2015.4838","volume":"175","author":"E Toledo","year":"2015","unstructured":"Toledo E, Salas-Salvad\u00f3 J, Donat-Vargas C, et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial: a randomized clinical trial. JAMA Intern Med. 2015;175(11):1752\u201360.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"19100_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1055-9965.EPI-05-0603","volume":"15","author":"B Tehard","year":"2006","unstructured":"Tehard B, Friedenreich CM, Oppert JM, et al. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev. 2006;15(1):57\u201364.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"33","key":"19100_CR6","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","volume":"37","author":"K Visvanathan","year":"2019","unstructured":"Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152\u201365.","journal-title":"J Clin Oncol"},{"issue":"1","key":"19100_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12609-023-00517-y","volume":"16","author":"C Marin","year":"2024","unstructured":"Marin C, Weiss A, Gooch JC. Chemoprevention\u2014Historical Perspectives and current trends. Curr Breast Cancer Rep. 2024;16(1):35\u201344.","journal-title":"Curr Breast Cancer Rep"},{"issue":"18","key":"19100_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"19100_CR9","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","volume":"28","author":"ME Ropka","year":"2010","unstructured":"Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"19100_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2002.20.1.9","volume":"20","author":"D Hershman","year":"2002","unstructured":"Hershman D, Sundararajan V, Jacobson JS, et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol. 2002;20(1):9\u201316.","journal-title":"J Clin Oncol"},{"issue":"2","key":"19100_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1245\/s10434-023-14566-1","volume":"31","author":"B Alhassan","year":"2024","unstructured":"Alhassan B, Rjeily MB, Villareal-Corpuz V, et al. Awareness and candidacy for endocrine prevention and risk reducing mastectomy in unaffected high-risk women referred for breast cancer risk assessment. Ann Surg Oncol. 2024;31(2):981\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"19100_CR12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37(19):1629\u201337.","journal-title":"J Clin Oncol"},{"issue":"2","key":"19100_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2013A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"33","key":"19100_CR14","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","volume":"37","author":"K Visvanathan","year":"2019","unstructured":"Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152\u201365.","journal-title":"J Clin Oncol"},{"issue":"17","key":"19100_CR15","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/JCO.22.02900","volume":"41","author":"M Lazzeroni","year":"2023","unstructured":"Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol. 2023;41(17):3116\u201321.","journal-title":"J Clin Oncol"},{"issue":"11","key":"19100_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/tbj.14296","volume":"27","author":"T Buttiron Webber","year":"2021","unstructured":"Buttiron Webber T, Marra D, Puntoni M, et al. Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer. Breast J. 2021;27(11):817\u201323.","journal-title":"Breast J"},{"issue":"2","key":"19100_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-022-06577-5","volume":"193","author":"B Bychkovsky","year":"2022","unstructured":"Bychkovsky B, Laws A, Katlin F, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Res Treat. 2022;193(2):417\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"19100_CR18","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.23.00455","volume":"41","author":"A Laws","year":"2023","unstructured":"Laws A, Punglia RS. Endocrine therapy for primary and secondary prevention after diagnosis of high-risk breast lesions or preinvasive breast cancer. J Clin Oncol. 2023;41(17):3092\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"19100_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/1940-6207.CAPR-24-0324","volume":"17","author":"LF Cornell","year":"2024","unstructured":"Cornell LF, Klassen CL, Ghosh K, et al. Improved uptake and adherence to risk-reducing medication with the use of low-dose tamoxifen in patients at high risk for breast cancer. Cancer Prev Res (Phila). 2024;17(12):565\u201370.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"19100_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"19100_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/tbj.13064","volume":"25","author":"CA Roche","year":"2019","unstructured":"Roche CA, Tang R, Coopey SB, et al. Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J. 2019;25(2):190\u20135.","journal-title":"Breast J"},{"issue":"1","key":"19100_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.breast.2014.11.006","volume":"24","author":"RG Roetzheim","year":"2015","unstructured":"Roetzheim RG, Lee JH, Fulp W, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast. 2015;24(1):51\u20136.","journal-title":"Breast"},{"issue":"7","key":"19100_CR23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","volume":"26","author":"MR Flanagan","year":"2019","unstructured":"Flanagan MR, Zabor EC, Stempel M, et al. Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol. 2019;26(7):2127\u201335.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"19100_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12609-016-0216-5","volume":"8","author":"S Hum","year":"2016","unstructured":"Hum S, Wu M, Pruthi S, et al. Physician and patient barriers to breast cancer preventive therapy. Curr Breast Cancer Rep. 2016;8(3):158\u201364.","journal-title":"Curr Breast Cancer Rep"},{"issue":"5","key":"19100_CR25","first-page":"624","volume":"52","author":"R Heisey","year":"2006","unstructured":"Heisey R, Pimlott N, Clemons M, et al. Women\u2019s views on chemoprevention of breast cancer: qualitative study. Can Fam Physician. 2006;52(5):624\u20135.","journal-title":"Can Fam Physician"},{"issue":"9","key":"19100_CR26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1158\/1940-6207.CAPR-11-0380","volume":"4","author":"JH Lin","year":"2011","unstructured":"Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila). 2011;4(9):1360\u20135.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"14","key":"19100_CR27","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/cncr.30644","volume":"123","author":"SM Wong","year":"2017","unstructured":"Wong SM, Stout NK, Punglia RS, et al. Breast cancer prevention strategies in lobular carcinoma in situ: a decision analysis. Cancer. 2017;123(14):2609\u201317.","journal-title":"Cancer"},{"issue":"1","key":"19100_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41416-023-02293-z","volume":"129","author":"M Hammarstr\u00f6m","year":"2023","unstructured":"Hammarstr\u00f6m M, Gabrielson M, Crippa A, et al. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. Br J Cancer. 2023;129(1):61\u201371.","journal-title":"Br J Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19100-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19100-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:31Z","timestamp":1776255931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19100-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["19100"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19100-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephanie Wong reports honoraria from AstraZeneca, Novartis, Pfizer, and Merck, outside of the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}